VALLI, MAURIZIA
 Distribuzione geografica
Continente #
NA - Nord America 1.196
EU - Europa 931
AS - Asia 590
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
AF - Africa 1
Totale 2.723
Nazione #
US - Stati Uniti d'America 1.193
CN - Cina 573
IE - Irlanda 311
UA - Ucraina 182
FI - Finlandia 127
DE - Germania 100
IT - Italia 61
GB - Regno Unito 58
SE - Svezia 40
FR - Francia 23
BE - Belgio 17
IR - Iran 10
IN - India 5
CA - Canada 3
ES - Italia 3
NL - Olanda 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
CH - Svizzera 1
EU - Europa 1
JP - Giappone 1
MU - Mauritius 1
PL - Polonia 1
RU - Federazione Russa 1
TR - Turchia 1
Totale 2.723
Città #
Dublin 311
Chandler 261
Jacksonville 219
Nanjing 144
Ashburn 115
Beijing 75
Nanchang 70
Ann Arbor 67
Shenyang 55
Lawrence 49
Medford 49
Princeton 49
Hebei 48
Changsha 46
Wilmington 44
Jiaxing 42
Helsinki 35
Boardman 31
Hangzhou 27
Tianjin 25
Woodbridge 21
Milan 20
Brussels 17
New York 16
Pavia 16
Washington 13
Shanghai 11
Verona 11
Auburn Hills 9
Ardabil 7
Norwalk 7
Zhengzhou 6
Des Moines 4
Houston 4
Jinan 4
Padova 4
Dearborn 3
Fairfield 3
Los Angeles 3
Pune 3
Sacramento 3
Villaralbo 3
Andover 2
Changchun 2
Falkenstein 2
Kunming 2
Leawood 2
Mainz 2
Ningbo 2
Perth 2
Redwood City 2
Toronto 2
Austin 1
Birmingham 1
Borås 1
Fuzhou 1
Guangzhou 1
Haikou 1
Lanzhou 1
Las Vegas 1
Montereale Valcellina 1
Napoli 1
Orange 1
Paris 1
Pitesti 1
Polska 1
San Francisco 1
Santa Clara 1
Seattle 1
Taizhou 1
Winnipeg 1
Zurich 1
Totale 1.990
Nome #
An in vitro test predictive of bioadhesive properties of chitosan films for buccal application 93
Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix. 90
5-METHYL-PYRROLIDINONE CHITOSAN FILMS AS CARRIRERS FOR BUCCAL ADMINISTRATION OF PROTEINS 87
A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo 84
Characterization of protein loaded 5-methyl-pyrrolidinone chitosan films 83
A de novo G to T transversion in a pro-a1(I) collagen gene for a moderate case of osteogenesis imperfecta. Substitution of cysteine for glycine 178 in the triple helical domain. 82
Rescue of migratory defects of Ehlers-Danlos syndrome fibroblasts in vitro by type V collagen but not insulin-like binding protein-1. 81
Bioadhesive films for buccal release of proteins 78
Deposition of mutant type I collagen in the extracellular matrix of cultured dermal fibroblasts in osteogenesis imperfecta. 77
Bioadhesive chitosan films for buccal release of proteins 77
Dipeptide loaded liposomes in photoaging: evaluation of cellular viability 73
A 931 + 2T-->C transition in one COL1A2 allele causes exon 16 skipping in PRO alpha 2(I) mRNA and produces moderately severe OI. 69
Direct monitoring of prolidase activity in cultured skin fibroblasts using capillary electrophoresis 68
Diagnosis of vascular Ehlers-Danlos syndrome in Italy: Clinical findings and novel COL3A1 mutations 68
Anomalous cysteine in type I collagen. Localisation by chemical cleavage of the protein using 2-nitro-5-thiocyanobenzoic acid and by mismatch analysis of cDNA heteroduplexes. 67
Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. 67
Severe nonlethal osteogenesis imperfecta: biochemical heterogeneity. 63
Direct monitoring of prolidase activity in cultured skin fibroblasts using capillary electrophoresis. 59
Extracellular matrix deposition in cultured dermal fibroblasts from four probands affected by osteogenesis imperfecta. 58
A base substitution at IVS-19 3'-end splice junction causes exon 20 skipping in pro alpha 2(I) collagen mRNA and produces mild osteogenesis imperfecta. 58
Isolation and characterization of two proteoglycans from bovine tendon 57
Phenotypic comparison of an osteogenesis imperfecta type IV proband with a de novo alpha2(I) Gly922 --> Ser substitution in type I collagen and an unrelated patient with an identical mutation. 55
Subependymal periventricular heterotopias in a patient with ehlers-danlos syndrome: a new case 54
Co-fibrillogenesis of Wild-type and D76N β2-Microglobulin: THE CRUCIAL ROLE OF FIBRILLAR SEEDS 53
Osteogenesis imperfecta and type I collagen mutations. A lethal variant caused by a Gly910->Ala substitution in the a1(I) chain. 52
Evaluation of bioadhesive performance of chitosan derivatives as films for buccal application 51
Four new cases of lethal osteogenesis imperfecta due to glycine substitutions in COL1A1 and genes. Mutations in brief no. 152. 51
Plasminogen activation triggers transthyretin amyloidogenesis in vitro 51
Possible role of overglycosylation in the type I collagen triple helical domain in the molecular pathogenesis of osteogenesis imperfecta. 50
Cutaneous metaplastic synovial cyst in Ehlers-Danlos syndrome: report of a second case. 50
Osteogenesis imperfecta: clinical, biochemical and molecular findings. 49
Identification of the amniotic fluid insulin-like growthfactor binding protein-1 phosphorylation sites andpropensity to proteolysis of the isoforms 49
Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. 48
Studio delle proprietà bioadesive del chitosano in funzione della veicolazione di farmaci proteici a livello buccale 48
Structure and properties of the C-terminal domain of insulin-like growth factor-binding protein-1 isolated from human amniotic fluid. 48
Severe (type III) osteogenesis imperfecta due to glycine substitutions in the central domain of the collagen triple helix. 47
Gly85 to Val substitution in proa1(I) chain causes mild osteogenesis imperfecta and introduces a susceptibility to protease digestion. 46
Mouse C127 cells transfection with fucosyltransferase Fuc-TIII express masked Lewis X but not Lewis X antigen 44
Cardiac valve disease: an unreported feature in Ehlers Danlos syndrome arthrocalasia type? 44
"In vitro" fibril formation of type I collagen from different sources: biochemical and morphological aspects. 43
Study of factors affecting the determination of total plasma 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBD)-thiol derivatives by liquid chromatography. 41
Mild dominant osteogenesis imperfecta with intrafamilial variability: the cause is a serine for glycine a1(I) 901 substitution in a type-I collagen gene. 38
Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor causes progressively deforming osteogenesis imperfecta with normal type I collagen. 36
Human Cells Unable to Express Decoron Produced Disorganized Extracellular Matrix Lacking “Shape Modules” (Interfibrillar Proteoglycan Bridges) 34
Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta. 34
Moderately severe osteogenesis imperfecta: biochemical studies showing variable defect localization in the triple-helical domain of type I collagen. 34
Paternal mosaicism for a COL1A1 dominant mutation (alpha 1 Ser-415) causes recurrent osteogenesis imperfecta. 32
Osteoblasts extracellular matrix induces vessel like structures through glycosylated collagen I. 22
Severe peripheral joint laxity is a distinctive clinical feature of spondylodysplastic-ehlers-danlos syndrome (Eds)-b4galt7 and spondylodysplastic-eds-b3galt6 16
Totale 2.759
Categoria #
all - tutte 8.460
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.460


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 5 1 1
2019/2020711 197 268 3 33 4 39 3 39 2 81 39 3
2020/2021309 47 28 7 35 1 39 6 46 6 48 40 6
2021/2022226 5 5 11 5 3 2 7 9 13 3 34 129
2022/2023798 77 60 2 70 88 74 1 37 353 10 18 8
2023/2024280 25 55 22 37 26 81 4 26 1 3 0 0
Totale 2.759